Remibrutinib-RHAPSIDO is a medicine that treats what

Remibrutinib - RHAPSIDO is a novel Bruton's tyrosine kinase (BTK) inhibitor specifically indicated for the treatment of chronic spontaneous urticaria (CSU). CSU is a skin disease in which patients often develop unpredictable symptoms of urticaria, including redness, swelling, and itching that last for six weeks or longer. The cause is unknown. Studies have shown that the occurrence of CSU is related to the abnormal activation of mast cells and basophils. These cells cause allergic reactions through the IgE or IgG antibody pathway, and BTK plays a key role in this signal transduction process.

Remibrutinib significantly alleviates the symptoms of CSU patients by inhibiting BTK and related kinases in mast cells and basophils, preventing the release of histamine and other pro-inflammatory mediators caused by IgE or IgG antibodies. Its therapeutic effect has been recognized by the U.S. Food and Drug Administration (FDA) based on the results of phase III clinical trials REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157). These studies showed that patients treated with remibrutinib demonstrated significant improvements in pruritus severity, cellulitis severity, and weekly disease activity at Day 7 and Week 12 compared with placebo controls. About one-third of patients were completely free of pruritus at week 12, demonstrating good disease control.

Patients taking remibrutinib should be taken orally twice daily, with or without food. However, there is an increased risk of bleeding when using this drug, and relevant warnings and precautions should be taken seriously. In addition, common adverse reactions include nasopharyngitis, bleeding, headache, nausea and abdominal pain, with incidence rates exceeding 3%. In addition to treating chronic spontaneous urticaria, remibrutinib is also in clinical development for the treatment of chronic induced urticaria, food allergy, and hidradenitis suppurativa.

Reference materials:https://www.drugs.com/rhapsido.html